Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

<p><strong>Background:</strong> Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their antiviral activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different antivir...

Полное описание

Библиографические подробности
Главные авторы: Schilling, WHK, Jittamala, P, Watson, JA, Boyd, S, Luvira, V, Siripoon, T, Ngamprasertchai, T, Batty, EM, Cruz, C, Callery, JJ, Singh, S, Saroj, M, Kruabkontho, V, Ngernseng, T, Tanglakmankhong, N, Tubprasert, J, Abdad, MY, Madmanee, W, Kouhathong, J, Suwannasin, K, Pagornrat, W, Piaraksa, N, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Poovorawan, K, Potaporn, M, Srisubat, A, Loharjun, B, Taylor, WRJ, Chotivanich, V, Chotivanich, K, Imwong, M, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ
Другие авторы: PLATCOV Collaborative Group
Формат: Journal article
Язык:English
Опубликовано: Elsevier 2023

Схожие документы